FZD7 and neoplasm: More selective antibodies and other therapeutics, such as those targeting FZD7, are being developed to inhibit canonical Wnt signaling specifically in cancers like colorectal and gastric tumors, where FZD7 overexpression drives tumor growth and resistance to apoptosis (Hua et al., 2022; Larasati et al., 2022).